Case Studies: Helping Entrepreneurs To Maximize Shareholder Value and Achieve Successful Exits
Entrepreneur Katherine Crothall, Ph.D., founder of Animas Corporation, developed an insulin pump for diabetes. We helped Animas raise a private equity financing. Animas subsequently completed a successful IPO and was acquired by Johnson & Johnson for $518 million.
Assisted Gentium in raising over $60 million through two PIPE financings. In addition, we acted as financial advisor to Gentium in the purchase of the Italian Defibrotide rights from Crinos S.p.A and in the re-negotiation of their existing licensing agreement with Sigma-Tau Pharmaceuticals. Gentium was acquired by Jazz Pharmaceuticals in 2014 for $1.0 billion.
Michael Jaharis and Daniel Bell, co-founders of Kos Pharmaceuticals, developed Niaspan® for lipid management. Junewicz & Co. advised the Company for over 10 years. During that time, Kos completed a successful IPO and was acquired by Abbott for $3.6 billion.
Acted as financial advisor to Medicis in the adoption of its original Shareholder Rights Plan. Medicis was acquired by Valeant in 2012 for $2.6 billion.
Entrepreneur Roger D. Griggs, founder of Richwood Pharmaceuticals, with our assistance, bought a diet drug (that also had an NDA for ADHD) for $1 million, re-positioned and re-named the drug ADDERALL®, and then sold Richwood to Shire plc for $187 million. ADDERALL® became the gold standard for ADHD.
|
Niaspan® is a registered trademark of AbbVie Inc.
ADDERALL® is a registered trademark of Shire plc.
ADDERALL® is a registered trademark of Shire plc.